Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: neuroprotectants - Cenomed BioSciences

X
Drug Profile

Research programme: neuroprotectants - Cenomed BioSciences

Alternative Names: Biodefense therapeutics - Cenomed BioSciences LLC; CB-2,501; Chemical defense programme - Cenomed BioSciences LLC; CM-2,501

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cenomed BioSciences LLC
  • Class Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Cholinergic receptor modulators; Imidazoline receptor agonists; Serotonin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neurological disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Neurological-disorders(Prevention) in USA
  • 30 Jun 2010 Celgene Corporation to acquire Abraxis BioScience
  • 25 Sep 2007 Cenomed BioSciences LLC establishes CRADA with the United States Army Medical Research Institute of Chemical Defense for the development of CM 2501 and related compounds as biodefense agents
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top